BioLargo, Inc.Financials
|
|
Historical Financials
DEC 2025 | DEC 2024 | DEC 2023 | DEC 2022 | DEC 2021 | DEC 2020 | DEC 2019 | DEC 2018 | DEC 2017 | DEC 2016 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 7,765,000 | 17,779,000 | 12,230,000 | 5,884,000 | 2,531,000 | 2,432,000 | 1,861,000 | 1,364,000 | 516,000 | 281,106 | |
| Cost of Revenue | 4,359,000 | 9,926,000 | 6,076,000 | 3,027,000 | 1,428,000 | 1,204,000 | 945,000 | 743,000 | 323,000 | 105,877 | |
| Gross Profit | 3,406,000 | 7,853,000 | 6,154,000 | 2,857,000 | 1,103,000 | 1,228,000 | 916,000 | 621,000 | 193,000 | 175,229 |
Sign up to view full financial statements
Create a free CapEdge account to access balance sheet, cash flow, and complete historical data.
DEC 2025 | DEC 2024 | DEC 2023 | DEC 2022 | DEC 2021 | DEC 2020 | DEC 2019 | DEC 2018 | DEC 2017 | DEC 2016 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin (%) | |||||||||||
| R&D Expense | |||||||||||
| SG&A Expense | |||||||||||
| Total Operating Expenses | |||||||||||
| Operating Income or Loss | |||||||||||
| Operating Margin (%) | |||||||||||
| EBITDA | |||||||||||
| Interest Expense | |||||||||||
| Non-Operating Income/Expense | |||||||||||
| Income Before Tax | |||||||||||
| Income Tax Expense | |||||||||||
| Income from Continuing Ops. | |||||||||||
| Net Profit Margin (%) | |||||||||||
| Basic EPS | |||||||||||
| Diluted EPS | |||||||||||
| Basic Average Shares |
All numbers in thousands. Financial statements are in beta and sourced from EDGAR XBRL filings. Read the caveats.